GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PMV Pharmaceuticals Inc (NAS:PMVP) » Definitions » Current Ratio

PMV Pharmaceuticals (PMV Pharmaceuticals) Current Ratio : 14.78 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is PMV Pharmaceuticals Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. PMV Pharmaceuticals's current ratio for the quarter that ended in Dec. 2023 was 14.78.

PMV Pharmaceuticals has a current ratio of 14.78. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for PMV Pharmaceuticals's Current Ratio or its related term are showing as below:

PMVP' s Current Ratio Range Over the Past 10 Years
Min: 14.78   Med: 23.73   Max: 56.9
Current: 14.78

During the past 6 years, PMV Pharmaceuticals's highest Current Ratio was 56.90. The lowest was 14.78. And the median was 23.73.

PMVP's Current Ratio is ranked better than
88.68% of 1555 companies
in the Biotechnology industry
Industry Median: 3.71 vs PMVP: 14.78

PMV Pharmaceuticals Current Ratio Historical Data

The historical data trend for PMV Pharmaceuticals's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PMV Pharmaceuticals Current Ratio Chart

PMV Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial 22.57 56.90 24.66 22.80 14.78

PMV Pharmaceuticals Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.80 22.03 16.63 19.16 14.78

Competitive Comparison of PMV Pharmaceuticals's Current Ratio

For the Biotechnology subindustry, PMV Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PMV Pharmaceuticals's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PMV Pharmaceuticals's Current Ratio distribution charts can be found below:

* The bar in red indicates where PMV Pharmaceuticals's Current Ratio falls into.



PMV Pharmaceuticals Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

PMV Pharmaceuticals's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=207.409/14.029
=14.78

PMV Pharmaceuticals's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=207.409/14.029
=14.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PMV Pharmaceuticals  (NAS:PMVP) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


PMV Pharmaceuticals Current Ratio Related Terms

Thank you for viewing the detailed overview of PMV Pharmaceuticals's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


PMV Pharmaceuticals (PMV Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1 Research Way, Princeton, NJ, USA, 08536
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
Executives
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Leila Alland officer: Chief Medical Officer C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Deepika Jalota officer: SVP, Regulatory Affairs and QA C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Orbimed Capital Gp V Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Kirsten Flowers director C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Thilo Schroeder director, 10 percent owner C/O NEXTECH INVEST LTD., BAHNHOFSTRASSE 18, ZURICH V8 8001
Arnold J Levine director C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
Winston Kung officer: COO, CFO C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
David Henry Mack director, officer: President and CEO ONE EMBARCADERO CENTER, SUITE 3700, SAN FRANCISCO CA 94111
Euclidean Capital Llc 10 percent owner 160 FIFTH AVE, 9TH FL, NEW YORK NY 10010
James H Simons 10 percent owner RENAISSANCE TECHNOLOGIES LLC, 800 THIRD AVE, NEW YORK NY 10022
Greenland A Llc 10 percent owner C/O EUCLIDEAN CAPITAL LLC, 160 FIFTH AVE, 9TH FL, NEW YORK NY 10010

PMV Pharmaceuticals (PMV Pharmaceuticals) Headlines

From GuruFocus